Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Checkpoint inhibitors are monoclonal antibodies that elicit an anti-tumor response by stimulating immune system. Their use has improved the treatment of different types of cancer such as melanoma, breast carcinoma, lung, stomach, colon, liver, renal cell carcinoma, and Hodgkin’s lymphoma, but severa...

Full description

Bibliographic Details
Main Authors:	Nicia I. Profili, Roberto Castelli, Antonio Gidaro, Alessandro Merella, Roberto Manetti, Giuseppe Palmieri, Margherita Maioli, Alessandro P. Delitala
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Journal of Clinical Medicine
Subjects:	immune checkpoint inhibitors endocrine side effects PD-1 PD-L1 CTLA-4 thyroid
Online Access:	https://www.mdpi.com/2077-0383/12/15/5161

Similar Items

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
by: Hanna Karhapää, et al.
Published: (2022-02-01)

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
by: Yinghong Zhai, et al.
Published: (2019-11-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

Immune Checkpoints and Innovative Therapies in Glioblastoma
by: Massimo Romani, et al.
Published: (2018-10-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
by: Deniz Can Guven, et al.
Published: (2022-10-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
by: Gabriel Surdacki, et al.
Published: (2019-03-01)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
by: Maria Stelmachowska-Banaś, et al.
Published: (2020-10-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
by: Mihnea Dragomir, et al.
Published: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
by: Maria Georganaki, et al.
Published: (2018-12-01)

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
by: Benjamin Y. Kong, et al.
Published: (2019-02-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors
by: Elisabetta Maria Abenavoli, et al.
Published: (2023-11-01)

Endocrine side effects of immune checkpoint inhibitors
by: Zulma Cardona, et al.
Published: (2023-05-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
by: Leona Raskova Kafkova, et al.
Published: (2024-02-01)

Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?
by: Elissavet Ntemou, et al.
Published: (2024-03-01)

Exploring the Significance of Immune Checkpoints and EBV Reactivation in Antibody Deficiencies with Near-Normal Immunoglobulin Levels or Hyperimmunoglobulinemia
by: Paulina Mertowska, et al.
Published: (2023-10-01)

Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
by: Norah A. Alturki
Published: (2023-06-01)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Chengdi Wang, et al.
Published: (2019-07-01)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
by: Seyed Hossein Kiaie, et al.
Published: (2023-09-01)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
by: Gwenyth J. Joseph, et al.
Published: (2023-12-01)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
by: Ming Yi, et al.
Published: (2019-03-01)

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
by: Michael Kuske, et al.
Published: (2022-03-01)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
by: Simona Duranti, et al.
Published: (2021-04-01)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
by: Trevor E. Angell, et al.
Published: (2018-03-01)

Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study
by: Jeffrey Shi Kai Chan, et al.
Published: (2023-04-01)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
by: Pei-Yi Chu, et al.
Published: (2021-10-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
by: Puneet Singh, et al.
Published: (2019-02-01)

Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science
by: Ya-Shan Chen, et al.
Published: (2015-02-01)

Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of  Small Cell Lung Cancer
by: Benlin HUANG, et al.
Published: (2019-04-01)

Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis
by: Lu Zhao, et al.
Published: (2021-12-01)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk
by: Marta Wagner, et al.
Published: (2021-01-01)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
by: Hongjing Zang, et al.
Published: (2020-04-01)